NASDAQ:NK - Nantkwest Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.18 -0.03 (-2.48 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$1.18
Today's Range$1.14 - $1.24
52-Week Range$0.93 - $5.09
Volume195,207 shs
Average Volume186,376 shs
Market Capitalization$93.49 million
P/E Ratio-0.98
Dividend YieldN/A
Beta2.7
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone858-633-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50,000.00
Book Value$2.75 per share

Profitability

Net Income$-96,420,000.00
Net Margins-198,790.38%

Miscellaneous

Employees139
Market Cap$93.49 million
Next Earnings Date3/11/2019 (Estimated)
OptionableOptionable

Nantkwest (NASDAQ:NK) Frequently Asked Questions

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) announced its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. Nantkwest had a negative return on equity of 54.20% and a negative net margin of 198,790.38%. View Nantkwest's Earnings History.

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Nantkwest.

What price target have analysts set for NK?

2 Wall Street analysts have issued 12-month target prices for Nantkwest's stock. Their predictions range from $2.00 to $3.50. On average, they expect Nantkwest's stock price to reach $2.75 in the next year. This suggests a possible upside of 133.1% from the stock's current price. View Analyst Price Targets for Nantkwest.

What is the consensus analysts' recommendation for Nantkwest?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.

Has Nantkwest been receiving favorable news coverage?

News coverage about NK stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nantkwest earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Trevena (TRVN), Fate Therapeutics (FATE), Bausch Health Companies (BHC), Novavax (NVAX), Sangamo Therapeutics (SGMO), Opko Health (OPK) and Exelixis (EXEL).

Who are Nantkwest's key executives?

Nantkwest's management team includes the folowing people:
  • Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
  • Mr. Richard J. Tajak, Consultant (Age 65)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 45)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)

When did Nantkwest IPO?

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.20%), Geode Capital Management LLC (0.42%), Candriam Luxembourg S.C.A. (0.29%), Dimensional Fund Advisors LP (0.29%), D. E. Shaw & Co. Inc. (0.23%) and Bank of New York Mellon Corp (0.13%). View Institutional Ownership Trends for Nantkwest.

Which major investors are selling Nantkwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp and Dimensional Fund Advisors LP. View Insider Buying and Selling for Nantkwest.

Which major investors are buying Nantkwest stock?

NK stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., D. E. Shaw & Co. Inc., Two Sigma Investments LP, SG Americas Securities LLC, Paloma Partners Management Co, Rhumbline Advisers and Geode Capital Management LLC. View Insider Buying and Selling for Nantkwest.

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $1.18.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $93.49 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is http://www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]


MarketBeat Community Rating for Nantkwest (NASDAQ NK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel